Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Titel:
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Auteur:
Cheng, Ann-Lii Cornelio, Gerardo Shen, Lin Price, Timothy Yang, Tsai-Sheng Chung, Ik Joo Dai, Guang-Hai Lin, Jen-Kou Sharma, Atul Yeh, Kun-Huei Ma, Brigette Zaatar, Adel Guan, Zhongzhen Masood, Nehal Srimuninnimit, Vichien Yau, Thomas Gibbs, Peter Wang, Xiuwen Doval, Dinesh Chandra Oh, Seung-Taek Shim, Byoung Yong Gorospe, Charity Wang, Hwei-Ming Sirachainan, Ekaphop Hill, Andrew Suh, Kwang Wook Beier, Frank Chatterjee, Sudipto Lim, Robert